Cite
HARVARD Citation
George, D. et al. (2019). Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist. pp. 1497-1501. [Online].